Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 1
2015 1
2016 3
2019 5
2020 7
2021 13
2022 7
2023 5
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. Wingerchuk DM, et al. Ann Neurol. 2021 Jun;89(6):1088-1098. doi: 10.1002/ana.26049. Epub 2021 Feb 27. Ann Neurol. 2021. PMID: 33586143 Free PMC article. Clinical Trial.
Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study.
Zaccone T, Moiola L, Guerrieri S, Nozzolillo A, Zanetta C, Gattuso I, Genchi A, Esposito F, Scarale MG, Rancoita PMV, Rocca MA; Clinical SanRaf MS Study Group; Filippi M. Zaccone T, et al. Among authors: nozzolillo a. J Neurol. 2025 Jun 28;272(7):481. doi: 10.1007/s00415-025-13224-8. J Neurol. 2025. PMID: 40581721
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
Lapucci C, Frau J, Cocco E, Coghe G, Petracca M, Lanzillo R, Brescia Morra V, Nicoletti CG, Landi D, Marfia G, Vercellino M, Cavalla P, Bianco A, Mirabella M, Torri Clerici V, Tomas E, Ferrò MT, Grossi P, Nozzolillo A, Moiola L, Zaffaroni M, Ronzoni M, Pinardi F, Novi G, Cellerino M, Uccelli A, Inglese M. Lapucci C, et al. Among authors: nozzolillo a. Mult Scler. 2024 Aug;30(9):1151-1162. doi: 10.1177/13524585241266509. Epub 2024 Aug 14. Mult Scler. 2024. PMID: 39143825
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C, Bovis F, Novi G, Capobianco M, Lanzillo R, Frau J, Repice AM, Hakiki B, Realmuto S, Bonavita S, Curti E, Brambilla L, Mataluni G, Cavalla P, Di Sapio A, Signoriello E, Barone S, Maniscalco GT, Maietta I, Maraffi I, Boffa G, Malucchi S, Nozzolillo A, Coghe G, Mechi C, Salemi G, Gallo A, Sacco R, Cellerino M, Malentacchi M, De Angelis M, Lorefice L, Magnani E, Prestipino E, Sperli F, Brescia Morra V, Fenu G, Barilaro A, Abbadessa G, Signori A, Granella F, Amato MP, Uccelli A, Gobbi C, Sormani MP. Zecca C, et al. Among authors: nozzolillo a. Mult Scler. 2020 Oct;26(12):1519-1531. doi: 10.1177/1352458519872889. Epub 2019 Oct 1. Mult Scler. 2020. PMID: 31573386
39 results